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Interferon-inducible transmembrane protein 3 (IFITM3) is an effector protein of the innate immune system. It confers potent,
cell-intrinsic resistance to infection by diverse enveloped viruses both in vitro and in vivo, including influenza viruses, West Nile
virus, and dengue virus. IFITM3 prevents cytosolic entry of these viruses by blocking complete virus envelope fusion with cell
endosomemembranes. Although the IFITM locus, which includes IFITM1, -2, -3, and -5, is present in mammalian species, this
locus has not been unambiguously identified or functionally characterized in avian species. Here, we show that the IFITM locus
exists in chickens and is syntenic with the IFITM locus in mammals. The chicken IFITM3 protein restricts cell infection by influ-
enza A viruses and lyssaviruses to a similar level as its human orthologue. Furthermore, we show that chicken IFITM3 is func-
tional in chicken cells and that knockdown of constitutive expression in chicken fibroblasts results in enhanced infection by in-
fluenza A virus. Chicken IFITM2 and -3 are constitutively expressed in all tissues examined, whereas IFITM1 is only expressed in
the bursa of Fabricius, gastrointestinal tract, cecal tonsil, and trachea. Despite being highly divergent at the amino acid level,
IFITM3 proteins of birds andmammals can restrict replication of viruses that are able to infect different host species, suggesting
IFITM proteins may provide a crucial barrier for zoonotic infections.
Type I and II interferons (IFNs) are critical for the developmentof the cell intrinsic antiviral state and achieve this by inducing
the expression of genes collectively named IFN-stimulated genes
(ISGs). Expression of the interferon-inducible transmembrane
(IFITM) genes (newmembers of the ISG family) restricts the rep-
lication of several highly pathogenic human viruses, including se-
vere acute respiratory syndrome (SARS) coronavirus, filoviruses
(Marburg virus and Ebola virus), influenza A viruses (IAVs), and
flaviviruses (dengue virus) (1, 2). Although restriction of HIV-1
infection has also been reported in some studies (3, 4), others have
failed to demonstrate such activity (1). IFITM proteins are small,
with an average size of 130 amino acids, and share a topology (5)
defined by a conserved CD225 domain (6). This domain consists
of two intramembrane (IM) regions and a conserved intracellular
loop (CIL).
As their names suggest, IFITM proteins are upregulated by
type I and II IFNs; however, some cell and tissue types express
constitutive levels of one ormore of these proteins (7). In humans,
IFITM1, -2, and -3 are expressed in a wide range of tissues, while
IFITM5 expression is limited to osteoblasts. Mice have ortho-
logues for IFITM1, -2, -3, and -5 and additional IFITM genes,
Ifitm6 and Ifitm7 (8). Genome analysis of chickens has predicted
the existence of two IFITMgenes, orthologous to human IFITM10
(huIFITM10) and huIFITM5 (9). However, such in silico analysis
is often confounded by inappropriate identification of pseudo-
genes and incorrect assignment of orthologues, due to an incom-
plete knowledge of IFITM gene duplication and evolutionary his-
tory of this locus during speciation. Under such circumstances,
careful genome analysis of syntenic regions and functional char-
acterization of genes are required to attempt to unambiguously
define orthologous genes.
IFITM proteins are the only mediators of innate immunity
known to inhibit viral infection by blocking cytoplasmic entry
and replication of diverse enveloped viruses (10). IFITM-me-
diated viral restriction occurs at entry sites of susceptible vi-
ruses, in the late endosomal and lysosomal compartments,
where the proteins are predicted to adopt an intramembrane
structure. The N and C termini of the proteins are predicted to
be cytoplasmic, the two intramembrane domains are buried
within the cytoplasmic facing lipid bilayer, and the CD225 do-
main is thought to be facing the cytoplasm (11). IFITM pro-
teins inhibit formation of a fusion pore between the virus and
endosomal membranes following acidic activation of virus en-
velope fusion proteins. Recently, the ability of IFITM proteins
to alter cellular membrane fluidity was demonstrated, leading
to the arrest of fusion pore formation at the stage of hemimem-
brane fusion (12). Furthermore, it was recently found that
IFITM3 interacts with vesicle-membrane-protein-associated
protein A (VAPA) and prevents its association with oxysterol-
binding protein (OSBP) (13), which disturbs intracellular cho-
lesterol homeostasis and thus causes inhibition of viral fusion
in the late endosome, by an unknown mechanism.
The high constitutive levels of IFITM proteins observed in
many tissues potentially provide a first line of defense against
virus infection. The induction of type I IFNs further promotes
IFITM expression, increasing their protective effect on sur-
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rounding uninfected cells. Depletion of Ifitm3 in mouse cells
results in a loss of 40% to 70% of IFN=s protective effect against
endosomal entering viruses (1). A similar attenuation is also
observed from cells derived from IfitmDel mice, lacking Ifitm1,
-2, -3, -5, and 6, suggesting IFITM3 accounts for most of the
antiviral activity of this locus for the viruses investigated (14).
Importantly, mice homozygous for Ifitm3 deletion suffer ful-
minant viral pneumonia when challenged with low-pathoge-
nicity IAV (14, 15). Direct clinical relevance of IFITM3’s in-
volvement in restricting human IAV infection has recently
been shown in individuals hospitalized with seasonal or pan-
demic influenza H1N1/09 viruses (15), where a statistically sig-
nificant number of hospitalized patients show overrepresenta-
tion of a minor C allele in IFITM3 (rs12252-C) that correlates
with a decrease in the ability of IFITM3 to restrict influenza
virus infection in vitro. Importantly, the significance of the
association of the rs12252-C allele with severe influenza infec-
tion was recently replicated in a Chinese cohort of patients
(16). Together, these data reveal that the action of IFITM3
profoundly alters the course of influenza virus infection in
mammals and that allelic variation in IFITM3 alters host sus-
ceptibility to severe influenza virus infection. Although IFITMs
have been well characterized in humans and mice, little com-
pelling functional data exists for this ISG family in other spe-
cies.
Avian IAVs represent a continuing threat to human popula-
tions both as a source for direct human infection and as a reservoir
for IAV genetic variation. These reservoirs provide the conditions
for the generation of reassorted IAVs with altered host ranges and
pandemic potential (17). Furthermore, endemic and emerging
avian viral pathogens createmajor challenges to the poultry indus-
try through loss of productivity and mortality. Similarly, lyssavi-
ruses, particularly rabies virus (RABV), pose a substantial public
health threat, with half of the world’s population living in areas of
endemicity (18), although reports of avian lyssavirus infections
are rare. The clinical presentations of an infection are identical for
all lyssavirus species; however, while current vaccines and postex-
posure prophylaxis provide sterilizing immunity against RABV
and genetically similar species, no such protection is conferred
against the more genetically diverse lyssaviruses (19). Intrinsic
innate immunity plays an important role in controlling the spread
of numerous enveloped viruses; however, the influence of the
IFITM ISGs on members of the Lyssavirus genus has not previ-
ously been evaluated. Although putative IFITM genes have been
identified by database searching in many species (6, 9), no formal
genome analysis or functional assessment of avian IFITM genes
has been undertaken. Here we report the analysis of the IFITM
locus, reaffirming the existence of chicken IFITM1 (chIFITM1)
and providing the first functional characterization of chIFITM2
and chIFITM3, as well as demonstrating restriction of endosome-
entering viruses by chIFITMs in vitro.
MATERIALS AND METHODS
Cell culture and generation of IFITM-expressing cell lines.Human-de-
rived A549 cells (CCL-185; ATCC) were grown in F-12 medium (Life
Technologies) and human HEK293T (CRL-1573; ATCC) and chicken
DF-1 (CRL-12203; ATCC) cells were grown in Dulbecco’s modified Ea-
gle’smedium (DMEM) (Life Technologies); allmediawere supplemented
with 10% (vol/vol) fetal bovine serum (FBS) (Biosera). Chicken and hu-
man IFITM gene sequences were synthesized (GeneArt; Life Technolo-
gies) as codon-optimized genes for expression in human cells, and
chicken IFITMs were also synthesized for optimal expression in chicken
cells. All IFITM genes were cloned into the BamHI and NotI sites of the
lentivirus vector, pSIN-BNHA (20), and sequences confirmed by capillary
sequencing (GATC Biotech). The gene cassette was cloned into pSIN-
BNHA, to ensure that a C-terminal hemagglutinin (HA) tag followed the
IFITM protein. Lentivirus vector stocks were made by a three-plasmid
transfection of HEK293T cells, grown to confluence in a 10-cm dish.
Briefly, 200 l of Opti-MEM (Gibco) was mixed with 10 l of Fugene-6
(Roche) before addition of 1 g of a gag-pol-expressing vector (p8.91), 1
g of a vesicular stomatitis virus glycoprotein (VSV-G)-expressing vector
(pMDG), and 1.5 g of vector expressing the transgene (pSIN-BNHA)
and incubated for 15 min. The medium was removed from the cells and
replaced with 8 ml of DMEM plus 10% fetal bovine serum (FBS), and
the DNA mixture was added dropwise to the cells. After 24 h at 37°C
and 5% CO2, the medium was removed and replaced with 8 ml DMEM
plus 10% FBS and incubated for a further 24 h. Packaged lentivirus
vector was harvested 48 and 72 h after transfection by collecting the
supernatant and being filtered through a 0.45-m-pore filter (Millex).
The lentiviruses were used to transduce human A549 lung epithelial
cells and produce a mixed population from which single cell clones
were derived by limiting dilution. Expression of IFITMs was detected
by HA flow cytometric analysis.
Confocal microscopy.Cells were seeded at 1 105/well on coverslips
in a 12-well plate 1 day prior to transfection with an IFITM-encoding
plasmid (1gDNAwith 3l of Fugene [Promega]). Cells were fixed with
100%methanol for 10min followed by being blocked in 1%bovine serum
albumin (BSA) for 30 min. The HA epitope was targeted by an anti-HA
antibody conjugated to Alexa Fluor 550 (ab117513), and endosomes were
visualized by a Lamp1 antibody with human (ab25630; Abcam) or
chicken (LEP100 IgG; Developmental Studies Hybridoma Bank) specific-
ity, followed by incubationwith a secondary antibody conjugated toAlexa
Fluor 488 (ab96871; Abcam).
Flow cytometric analysis. Transfected cells were harvested using 300
l 0.25% trypsin-EDTA (Life Technologies), neutralized with 300 l of
cell culture medium plus 10% FBS, and pooled with the supernatant. The
cells were spun at 2,000 g for 5 min, and the pellet was resuspended in
100 l PBS and transferred to a 96-well V-bottomed plate (Nunc). The
plate was centrifuged, and the cells were fixed and permeabilized in 100l
of Cytofix/Cytopermbuffer (Becton,Dickinson) andwashed according to
the manufacturer’s guidelines. The cells were resuspended with the an-
ti-HA antibody conjugated to fluorescein isothiocyanate (FITC) (A190-
108F; Cambridge Bioscience) and incubated for 1 h at 4°C, followed by
two rounds of washing. IAV replication was detected by antinucleopro-
tein (anti-NP) antibody (ab128193; Abcam) followed by incubation with
anti-mouse Alexa Fluor 650 (ab96882; Abcam). Cells were resuspended in
300l of PBS before analysis by flow cytometry (FACSCalibur II; Becton,
Dickinson).
Infection of IFITM-expressing cell lines with pseudotyped viruses.
Chicken or human IFITM-expressing A549 cell lines were seeded at 3
103 cells/well in 96-well plates 1 day prior to infection with either green
fluorescent protein (GFP)-expressing pseudotyped lyssaviruses, RABV
challenge virus standard 11 (CVS-11; GenBank accession no. EU352767)
and Lagos bat virus (LBV) (LBV.NIG56-RV1; GenBank accession no.
HM623779), luciferase-expressing pseudotyped influenza viruses (HA1
[GenBank accession no. AF117241], HA5 [GenBank accession no.
EF541394], H7 [GenBank accession no. AJ491720], and H10 [GenBank
accession no. CY014671]) or amphotrophic murine leukemia virus
(MLV-A). GFP expression, as a measure of lentivirus infection, was de-
termined by fluorescence microscopy at 48 h postinfection following fix-
ation (20 min) with 4% (vol/vol) paraformaldehyde (USB) and permea-
bilization (10min) using 0.3%Triton X–PBS. Cells were washed with 100
l of PBS-Hoechst solution (Life Technologies) (200 ng/l), and a plate
seal was adhered. The fixed cells were analyzed to determine the propor-
tion of cells expressing GFP (Cellomics ArrayScan VTI; Thermofisher),
Smith et al.
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using the Target Activation bioapplication. Briefly, this method counts
every cell on the plate by drawing a perimeter around each of the nuclei
(detected by Hoechst) and calculates the percentage of these cells also
expressing GFP. Luciferase activity, as a measure of lentivirus infection,
was determined at 48 h postexposure using 50l Bright-Glo reagent (Pro-
mega). The cells were allowed to lyse for 2min before the level of luciferase
activity was measured using the FLUOstar Omega (BMG Labtech). GFP
and luciferase levels are reported relative to infection of A549 cells in the
absence of IFITM protein overexpression.
siRNA knockdown studies.DF-1 chicken cells were seeded at 5 104
cells/well in a 24-well plate and transfected with a small interfering RNA
(siRNA) against chIFITM3 (GCGAAGTACCTGAACATCACG) or a
nonspecific siRNA (UUCUCCGAACGUGUCACGUGU), using Lipo-
fectamine RNAiMAX (Life Technologies) 48 h prior to IFN stimulation.
The cells were stimulated by addition of either 200 ng/ml of chicken IFN-
(RP0115c; Kingfisher Biotech) or chicken IFN- (PAP004; AbD Serotec)
for a further 24 h or infectedwith IAV (A/WSN/1933 [WSN/33]) for 1 h at
a multiplicity of infection (MOI) of 0.1. RNA was extracted according to
the manufacturer’s instructions (RNeasy minikit; Qiagen). Reverse tran-
scription-PCR (RT-PCR)was performed (QuantiTectMultiplexRT-PCR
kit; Qiagen) using probes and primers fromABI (chicken glyceraldehyde-
3-phosphate dehydrogenase [GADPH], 4448489; and chicken_IFITM3,
custom assay). Influenza virus infection wasmeasured by flow cytometric
analysis (see above) using an anti-NP antibody (ab20921; Abcam) to de-
termine cell infection.
Plaque assays. Material to be assayed was serially diluted in serum-
free DMEM and used to infect MDCK cells in 12-well plates. After 1 h of
incubation, the inoculum was removed, and the cells were overlaid with
DMEM containing 0.2% BSA (Sigma-Aldrich), 1.25% Avicel (FMC
Biopolymer), and 1 g trypsin ml1 (21). After 2 days, the overlay was
removed, and the cells were fixed with 4% formal saline–PBS solution for
20 min before being stained with 0.1% toluidine blue solution (Sigma-
Aldrich) so that the number of PFU could be calculated.
Expression of IFITM proteins in different chicken tissues. Tissues
were removed from 3-week-old specific pathogen-free (SPF) Rhode Is-
land Red (RIR) chickens, specifically thymus, spleen, bursa of Fabricius,
cecal tonsil, gastrointestinal tract, trachea, bone marrow, brain, muscle,
heart, liver, kidney, lung, and skin. RNA was DNase treated, and reverse
transcription was carried out (SuperScript III reverse transcriptase; Life
Technologies). The cDNA from each tissue was amplified by PCR using
the following primer sets: chIFITM1 (F=-AGCACACCAGCATCAACA
TGC, R=-CTACGAAGTCCTTGGCGATGA), chIFITM2 (F=-AGGTGAG
CATCCCGCTGCAC, R=-ACCGCCGAGCACCTTCCAGG), chIFITM3
(F=-GGAGTCCCACCGTATGAAC, R=-GGCGTCTCCACCGTCACCA),
and chicken_GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (F=-
ACTGTCAAGGCTGAGAACGG, R=-GCTGAGGGAGCTGAGATGA).
RESULTS
Identification of the chicken IFITM locus. The chicken genome
(ENSEMBLbrowser, version2.1) contains twoputative IFITMgenes
on chromosome 5, the so-called IFITM5 (ENSGALG00000004239;
chromosome 5:1620304 to 1621805:1) and IFITM10 (ENSGAL
G00000020497; chromosome 5:15244061 to 15249351:1). The puta-
tive IFITM5 gene is located next to an uncharacterized gene
(ENSGALG00000006478), with which it shares 30% amino acid
identity. Immediately adjacent to this are three sequence gaps whose
estimated sizes are 1 kb, 1 kb, and 400 bp in the ENSEMBL chicken
genome build. Importantly, the putative IFITM genes in chicken are
flanked by the telomeric -1,4-N-acetyl-galactosaminyl transferase
4 (B4GALNT4) gene and the centromeric acid trehalase-like 1
(ATHL1) gene. TheB4GALNT4 andATHL1 genes flank the antiviral
IFITM 1, 2, -3, and -5 gene block inmammalian genomes. Sequence
similarity searches of the most recent build of the chicken genome
(v4.0, NCBI) using TBLASTN analysis and the putative IFITM5
amino acid sequence, revealed several transcripts with high amino
acid identity to IFITM5.Additionally,BLASThitswerealso identified
to putative genes LOC770612 and LOC422993, within the locus
flanked by B4GALNT4 and ATHL1. Between these putative genes,
two BLAST hits span the exons of genes designated chicken IFITM3-
like (NCBI, LOC422993; GenBank accession no. XM_420925.4)
and IFITM1-like (NCBI LOC770612; GenBank accession no.
XM_001233949.3). A third BLAST hit matches an uncurated gene,
“gene 376074,” which is positioned between IFITM3-like and
IFITM5. Further analysisof gene376074 showed it sharedaminoacid
sequence identity with both IFITM3-like and IFITM1-like genes. Se-
quence similarity searches of the NCBI chicken expressed sequence
tag (EST) database suggests gene 376074 is expressed. All of the ch-
IFITM paralogues, like mammalian IFITMs, are comprised of two
exons, and the location of the intron-exon boundary is conserved
across all of the chicken IFITMgenes. Therefore, the chicken genome
contains an intact IFITM locus with four putative IFITM genes
flanked by the genes B4GALNT4 and ATHL1 (Fig. 1A).
Annotation of the chicken IFITM genes. Using genome syn-
teny, we ascribe chIFITM5 as orthologous tomammalian IFITM5,
gene 376074 as orthologous to IFITM2, LOC422993 (IFITM3-
like) as orthologous to IFITM1, and LOC770612 (IFITM1-like) as
orthologous to IFITM3.Multiple amino acid sequence alignments
between the three predicted antiviral chIFITM genes and direct
orthologues in primate species suggest this assignment is plausi-
ble. A number of conserved IFITM family motifs are present in
some of the chicken sequences (Fig. 1B), and although the chicken
sequences differ significantly from the human and chimpanzee
orthologues, many amino acids in the CIL domain are conserved.
Multiple sequence alignments also reveal important amino acids
in the chicken IFITMs that help to categorize each sequence as
either IFITM1 or IFITM2/3. Tyr20 is conserved in all primate
IFITM2 or -3 sequences and is also present in chicken “IFITM1-
like” (NCBI) but none of the other IFITM1 orthologues. This, as
well as the longer N terminus, further supports our assessment of
this gene as an IFITM2 or -3 gene, and by synteny, the gene is
IFITM3. The alignment also reveals that other functionally signif-
icant amino acids are conserved in some of the chicken IFITM
sequences, including the two cysteines (Cys75 and -76) in IM1
that are palmitoylation sites in other species (11) and are impor-
tant for membrane positioning. Phe79, also in IM1, is conserved
in chicken “IFITM1-like” (chIFITM3), which is believed to be im-
portant for mediation of a physical association between IFITM
proteins (22). In light of syntenic analysis (and functional support
shown later), we suggest the following revisions of the NCBI no-
menclature: LOC770612 as chIFITM3 (previously “IFITM1-
like”), LOC422993 as chIFITM1 (previously chicken “IFITM3-
like”), and gene 376074 as chIFITM2 (Fig. 1).
Subcellular localization of IFITM proteins.Human IFITM1,
-2, and -3 localize distinctly in the cell, with IFITM1 being pre-
dominantly cell surface expressed and IFITM2 and -3 being pre-
dominantly intracellular, localizing with endosomes (Fig. 2D and
E). The cellular localization of IFITM proteins can further delin-
eate their orthologous relationships. We therefore synthesized
codon-optimized, C-terminal HA-tagged chIFITM1, -2, and -3
and transiently transfected chicken DF-1 fibroblasts, comparing
their cellular localization to the orthologous human IFITM (hu-
IFITM)proteins expressed in humanA549 cells. Confocalmicros-
copy using an anti-HA antibody and an anti-LAMP1 antibody
showed chIFITM1 was diffusely expressed throughout the cyto-
Chicken IFITM3
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plasm, and chIFITM2 was present in the cytoplasm and the cell
membrane, whereas chIFITM3 localized perinuclearly (Fig. 2A to
C), consistent with huIFITM3. chIFITM3 therefore shares syn-
teny, amino acid similarity, and subcellular localization with hu-
IFITM3. In the case of the other two chIFITMs, their localization
is a less clearly paired with the human IFITMs; thus, our nomen-
clature is founded on the gene order.
Chicken IFITM proteins restrict diverse virus infection.We
investigated if, despite considerable amino acid sequence diver-
gence, chicken IFITMs could function as restriction factors. By
expressing chIFITM3 at different levels in the cell, we show that
there is a strong expression-level-dependent correlation between
the level of chIFITM3 expression and the percentage of cells in-
fected by a lentivirus vector pseudotyped with the lyssavirus en-
velope of LBV (Fig. 3). We then compared the level of antiviral
restriction of chicken IFITM2 and -3 to that of their orthologous
human proteins in A549 cells. Overexpression of chIFITM3 re-
sulted in 79.4% and 85% reductions in infection of A549s to len-
tivirus vectors pseudotyped with the lyssaviruses envelopes RABV
and LBV, similar to the level of restriction by huIFITM3 to the
same viruses (Fig. 4A), even though chickens are rarely infected by
lyssaviruses (23). chIFITM2 also restricts lyssavirus LBV and
RABV infection to a similar level as chIFITM3.A similar pattern of
restriction is seen for lentiviruses pseudotyped with IAV H1, H5,
H7, and H10 (Fig. 4B). huIFITM3 restricts viral infection of all
influenza virus hemagglutinins, reducing infection by greater than
90%, and chIFITM3 restricts H1 and H10 pseudotypes as effec-
tively, but restricts H5 andH7 less well. chIFITM2 and huIFITM2
restrict more moderately, as shown by others. Consistent with
previous studies on huIFITM3 protein (1, 2), chIFITM3 failed to
restrict MLV-A (Fig. 4D). Overall, although chIFITM3 and hu-
IFITM3 only share 42% amino acid identity, the level of viral
restriction of chIFITM3 is similar to that in huIFITM3. Data are
not shown for chIFITM1, as a stably expressing cell line could not
bemade; this lack of stability at high expression levels is supported
by Hach et al. (24), who show that overexpression of unpalmitoy-
lated murine IFITM1 is difficult to achieve.
Ablationof IFITMexpression in chickenDF-1 cells increases
infection. We assessed the constitutive level of expression of
chIFITM3 in DF-1 cells, by quantitative RT-PCR with primers for
chIFITM3. DF-1 cells abundantly express chIFITM3 (threshold
cycles [CTs] of 20 for IFITM3 and 22 for GAPDH). Despite being
IFN inducible, addition of IFN- resulted in only a moderate in-
duction, whereas addition of IFN- caused a 2.67-log2 (6.4-fold)
increase in chIFITM3 expression (Fig. 5A).We assessed our ability
to knock down chIFITM3 expression inDF-1 cells using an siRNA
FIG 1 The chIFITM locus architecture and sequence. The IFITM gene cluster on Gallus gallus chromosome 5 is flanked by genes ATHL1 and B4GALNT4. This
region is syntenicwith the IFITM gene cluster on human chromosome 11 (A).Note that the orientation change of chIFITM2 and chIFITM1makes the assignment
of orthology difficult; therefore, the chicken genes are named by gene order and conservation of specific functionally defined amino acid residues. The predicted
mass is shown above the gene block. The colored columns in the sequence alignment (B) show residues that are shared between all nine IFITM sequences from
humans, chimpanzees, and chickens. Significant residues have been highlighted with a symbol below the sequence: o, tyrosine; Œ, double cysteine; star,
phenylalanine important for multimerization;1, conserved ubiquitinated lysine. IM1, intramembrane 1; CIL, conserved intracellular loop; IM2, intramem-
brane 2.
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designed to the chIFITM3 transcript. Treatment with this siRNA
on unstimulated DF-1 cells resulted in a 1.23-log2 (2.4-fold) re-
duction in the transcript level, with no change in chIFITM3 tran-
script abundance with a nonspecific siRNA. Knockdown of en-
dogenous chIFITM3 resulted in a greater than 2-fold increase in
infection of DF-1 cells by replication-competent influenza A virus
(A/WSN/1933) (Fig. 5B), assayed by flow cytometric analysis of
NP expression. Furthermore, overexpression of chIFITM3 in
DF-1 cells reduced viral replication by an average of 55% (Fig.
5D), and plaque assays show that the viral load was reduced from
1.3 106 PFUml1 to 3.1 105 PFUml1 after chIFITM3 over-
expression (Fig. 5E). Together, these results show chIFITM3 is
able to restrict IAV entry into DF-1 cells.
Differential expression of chIFITMs in chicken tissues. We
assessed the tissue-specific gene expression pattern in chickens
using a panel of RNA extracted from tissues from 3-week-old
FIG 2 Cellular localization of overexpressed IFITM proteins. Confocal microscopy of DF-1 cells transfected with chIFITM proteins 1 to 3 (A, B, and C) and
A549s transfectedwith huIFITMproteins 1 to 3 (D, E, and F) in the absence of infection. Panels show nuclei stainedwithDAPI (4=,6-diamidino-2-phenylindole)
(blue), endosomes marked with an antibody against Lamp1 (green), IFITM protein marked by an antibody against the HA tag (red), and a merged image.
Chicken IFITM3
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Rhode Island Red (RIR) chickens focusing on thymus, spleen,
bursa of Fabricius, cecal tonsil, trachea, gastrointestinal tract,
bone marrow, brain, muscle, heart, liver, kidney, lung, and skin.
Using primers specific to chIFITM1, -2, or -3 (Fig. 6), expression
of chIFITM2 and -3was detected in all tissues, althoughwith lower
levels of expression in themuscle and brain andhigher levels in the
cecal tonsils (Fig. 6). In contrast, expression of chIFITM1 was
more restricted and confined to the bursa of Fabricius, the gastro-
intestinal tract, and the cecal tonsil.
DISCUSSION
Todate, the antiviral activities of the IFITM2and IFITM3proteins
have only been demonstrated in mammals, with a single report
characterizing the function of chicken IFITM1 and IFITM5 (2).
Computational analysis of vertebrate genomes suggests the IFITM
gene family is present throughout vertebrates. However, this anal-
ysis and any phylogenetic reconstruction of gene history are com-
plicated by the paralogous nature of the IFITM gene family, the
presence of copy number variations, and the presence of numer-
ous processed pseudogenes (6). Indeed, the identification of avian
IFITMs as part of the dispanin protein family failed to identify
chicken IFITMs in the antiviral IFITM1- to -3 subfamily defined
as DSP2a to -c (25). Similarly, a more thorough analysis of verte-
brate IFITMs, while identifying distantly related IFITMs in rep-
tiles and birds, focused on eutherian clade 1 sequences for a de-
tailed phylogenetic analysis (9). Hickford et al. (26) have
undertaken a comprehensive analysis of IFITM genes across a
broad range of chordates. The authors have shown that all of the
species analyzed, including “lower” vertebrates, such as lampreys,
possess at least one IFITM-like gene. Phylogenetic analysis of all of
the IFITM paralogues they identified revealed that IFITM5
emerged in bony fish, while IFITM10 appears restricted to tetra-
pods. Here we have resolved the entire antiviral IFITM locus on
chromosome 5 of the chicken genome, expanding the number of
IFITM genes to 4 in this locus, and confirmed that the locus is
flanked by the genes ATHL1 and B4GALNT4 (9). Crucially, we
have shown that antiviral activity is conserved in chicken IFITMs.
The low-level sequence identity and orientation change of ch-
IFITM2 and chIFITM1 make the phylogenetic assignment of or-
thology problematic. Our revised nomenclature of the chicken
IFITM locus is based on the syntenic gene order, as previously
discussed, and functional data where possible. However, given
chIFITM2 is localized to the plasmamembrane, and the lack of an
N-terminal extension (characteristic of huIFITM2/3), it is possi-
ble that it is analogous to huIFITM1. It is likely that similar exten-
sive genetic and functional analyses will be essential to character-
ize the IFITM loci in other vertebrate species and define
unambiguously IFITM1, -2, and -3 orthologues.
Using the chIFITM3 amino acid sequence, we also searched the
duck genome (v1.0) and identified a scaffold (2943) containing
two duck IFITM (duIFITM) orthologues. Sequence identity and
conserved synteny with the chIFITM locus indicate they are
IFITM5 and IFITM1. The two IFITM flanking genes, B4GALNT4
and ATHL1, are also located on the scaffold in conserved posi-
tions. Although annotated gene structures are absent in the
browser, IFITM cDNAs in other avian species align with the re-
gions adjacent to both ends of the IFITM1 structure. This suggests
the duck retains four IFITM genes at a conserved locus.Wewould
FIG 3 An increase in the expression of chIFITM3 is associated with a decrease in viral infection. A range of clonal A549 cell populations expressing increasing
levels of chIFITM3 protein (bars A to G) were assessed byWestern blotting of the HA tag (B). These cell lines were infected by a lentivirus pseudotyped with the
Lagos bat virus (LBV) glycoprotein, and the replication was measured by GFP expression relative to that in untransduced A549s (A). Error bars show standard
deviations of the means (n 3).
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expect the positions of duIFITM2 and duIFITM3 to be conserved
with their orthologues in the chicken and other species. Following
infection with twoH5N1 strains of avian influenza virus (A/duck/
Hubei/49/05 and A/goose/Hubei/65/05), levels of expression of
duck IFITM3, -5, and -10 (measured by RNAseq) were increased
to various degrees, reflecting a response befitting their expected
function (27).
Control of animal pathogens, especially those with zoonotic
potential, is a key component of ensuring human health and food
security. RABV is responsible for approximately 70,000 human
deaths each year (28), while other lyssaviruses have only been
conclusively shown to cause a handful of fatalities (29), although
this could be due to poor surveillance. Our results are the first to
show diverse members of this genus of virus are sensitive to the
inhibitory action of human IFITM proteins. Furthermore, al-
thoughmost warm-blooded animals are susceptible to RABV, do-
mestic birds are rarely infected by lyssaviruses (23). Despite this,
chIFITM2 and -3 were able to significantly reduce cell lyssavi-
rus infection. Avian IAV infections, however, pose significant
threats to human health, to the international poultry industry,
and to small-scale poultry farmers (30). Our identification and
functional characterization of the avian IFITM locus, together
with knowledge that this gene family exists with copy number and
allelic variants in other species (9, 15, 16), should provide a focus for
identifying IFITMvariants with enhanced antiviral activity for use in
farm animal breeding strategies to improve animal infectious disease
resistance. Specifically, we hypothesize that certain wild or outbred
chicken IFITM allelic variants will confer enhanced levels of protec-
tion to pathogenic avian viruses that enter through acidic endosomes
and that breeding for enhanced activity in IFITM variants will im-
provedisease resistance in chickens. Similarly, should chicken IFITM
proteins restrict IAV infection in chick embryos, the ablation of IF-
ITMproteinexpressioncould improvevaccineproductionandboost
yield.
FIG 4 Human and chicken IFITM proteins restrict cell infection. Stable cell lines expressing human and chicken IFITM2 and -3 were infected by
pseudotyped viruses with either lyssavirus glycoprotein envelopes (RABV [CVS-11]) and LBV (LBV.NIG56-RV1) (A) or IAV hemagglutinin envelopes
(H1 [human], H5 [human], H7 [bird], or H10 [bird]) (B). The relative level of infection compared to untransduced A549 cells was measured by GFP
expression or luciferase activity for the lyssavirus and IAV envelope pseudotypes, respectively. Error bars represent standard deviations across two
biological replicates, each performed in triplicate. The expression levels of each cell line are shown byWestern blotting (C) relative to endogenous B-actin.
The stable cell line expressing chIFITM3 was infected with a pseudotyped virus expressing a luciferase reporter gene and the murine leukemia virus
(MLV-A) envelope as a control (D).
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We have shown that chIFITM proteins expressed in A549
cells are capable of restricting diverse viruses that enter cells
through the acidic endosome pathway. Furthermore, we show
that DF-1 chicken cells constitutively express chIFITM3, and
this is able to restrict influenza virus infection in vitro. Despite
sharing less than 50% amino acid identity, both chIFITM3 and
huIFITM3 effectively restrict the entry of all lyssavirus and IAV
envelope pseudotypes tested. Nevertheless, certain key amino
acids in the N terminus, IM1, and CIL domain are conserved in
chicken and human IFITM3, suggesting functional impor-
tance.
This work describes our elucidation of the IFITM locus in
the chicken genome and provides the first functional charac-
terization of chIFITM2 and chIFITM3. Despite this, many key
questions remain; it is unclear how genes such as IFITM3 in
humans and chickens, separated by 310 million years of evolu-
tion (31) and sharing less than 50% amino acid identity, main-
tain a conserved cellular location and a strong antiviral activity
against a diverse range of viruses. It is of equal importance to
determine, given the level of antiviral activity and the proposed
indirect mechanism of IFITM protein restriction (12, 13), how
viruses overcome the restriction either within or between spe-
cies. Investigation of appropriately defined IFITM loci from
different host species where cross-species transfer of virus in-
FIG 5 Chicken IFITM3 has an antiviral activity in DF-1 chicken cells. The expression level and log fold change of chIFITM3 were measured using quantitative
RT-PCR after stimulationwith IFN- and IFN- or after preincubationwith a nontargeting siRNAor one specific to chIFITM3 (A). The effect of knocking down
endogenous chIFITM3 expression in DF-1 cells infected with influenza A virus (A/WSN/1933 [WSN/33]) was measured by flow cytometry using an antibody
against nucleoprotein (NP) (B). P  0.01, Student’s t test. DF-1 cells transfected with chIFITM3-HA were infected by WSN. Expression of HA and NP was
detected by flow cytometry (C and D), and viral titers were measured by PFU (E). Error bars represent standard deviations across each condition performed in
triplicate.
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fection occurs may help explain barriers and vulnerabilities to
infection by diverse viruses.
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